Bayer shares up after first trial win over Roundup


BERLIN, Oct 6 (Reuters) – Shares in Bayer AG (BAYGn.DE) rose 2.5% in pre-market commerce on Wednesday after the German agricultural and prescribed drugs agency received its first trial over claims its Roundup weedkiller causes most cancers.

A California jury discovered that the herbicide was not a considerable trigger of a kid’s uncommon type of non-Hodgkin’s lymphoma, the corporate stated on Tuesday. The verdict is the fourth involving Roundup and the primary within the firm’s favor. learn extra

Roundup-related lawsuits have dogged Bayer because it acquired the model as a part of its $63 billion buy of agricultural seeds and pesticides maker Monsanto in 2018.

Reporting by Emma Thomasson; Editing by Muralikumar Anantharaman

Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay